In support of this study, the contribution of cathepsins to pathophysiological changes in MPS IIIB patients has been examined, and they were shown to be involved in the onset and progression of neuropathology and skeletal disorders in MPSs. This evidence concerns the gene CTSS and mucopolysaccharidosis type 3B.